May 16 |
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
|
May 9 |
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
|
May 9 |
Matinas Biopharma GAAP EPS of -$0.03 in-line, no revenue
|
May 9 |
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
|
May 8 |
Matinas Biopharma Q1 2024 Earnings Preview
|
May 7 |
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presentations at the ASGCT Annual Meeting
|
Apr 30 |
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
|
Apr 3 |
Matinas BioPharma prices $10 million registered direct offering
|
Apr 3 |
Matinas BioPharma Prices $10 Million Registered Direct Offering
|
Apr 1 |
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
|